Cardiotoxicity of trastuzumab emtansine (T-DM1): a single-center experience
Objective New anti-cancer drugs promise to increased survival benefits and reduce adverse events. Trastuzumab emtansine (T-DM1) is a novel anti-human epidermal growth factor receptor 2 agent that has shown minimal cardiotoxicity in clinical trials. However, data on real-life outcomes are required. M...
Sábháilte in:
| Príomhchruthaitheoirí: | , , , , , , |
|---|---|
| Formáid: | Artigo |
| Teanga: | Inglês |
| Foilsithe / Cruthaithe: |
SAGE Publishing
2021-12-01
|
| Sraith: | Journal of International Medical Research |
| Rochtain ar líne: | https://doi.org/10.1177/03000605211053755 |
| Clibeanna: |
Níl clibeanna ann, Bí ar an gcéad duine le clib a chur leis an taifead seo!
|